Gene polymorphisms affect postoperative imatinib plasma levels and edema in adults with gastrointestinal stromal tumor

Pharmacogenomics. 2023 May;24(7):425-434. doi: 10.2217/pgs-2022-0171. Epub 2023 May 22.

Abstract

Aim: To assess the role of genetic polymorphisms in postoperative imatinib concentrations and edema in patients with gastrointestinal stromal tumor. Methods: The relationships between genetic polymorphisms, imatinib concentrations and edema were explored. Results: Carriers of the rs683369 G-allele and rs2231142 T-allele had significantly higher imatinib concentrations. Grade ≥2 periorbital edemas were related to the carriership of two C-alleles in rs2072454 with an adjusted odds ratio of 2.85, two T-alleles in rs1867351 with an adjusted odds ratio of 3.42 and two A-alleles in rs11636419 with an adjusted odds ratio of 3.15. Conclusion: rs683369 and rs2231142 affect the metabolism of imatinib; rs2072454, rs1867351 and rs11636419 are related to grade ≥2 periorbital edemas.

Keywords: blood concentration; gastrointestinal stromal tumors; imatinib; periorbital edema; pharmacogenomics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Agents* / therapeutic use
  • Edema / genetics
  • Gastrointestinal Stromal Tumors* / drug therapy
  • Gastrointestinal Stromal Tumors* / genetics
  • Humans
  • Imatinib Mesylate / adverse effects
  • Polymorphism, Genetic

Substances

  • Imatinib Mesylate
  • Antineoplastic Agents